Mpox vaccine study aims to uncover immune secrets in HIV patients
NCT ID NCT05654883
First seen Oct 31, 2025 · Last updated Apr 26, 2026 · Updated 25 times
Summary
This study will enroll 174 adults in New York City to see how well the mpox vaccine works in people with HIV compared to those without HIV. Researchers will test two ways of giving the vaccine: a low-dose shot in the forearm and a standard-dose shot in the upper arm. The goal is to learn more about immune responses and side effects, helping to improve vaccine recommendations for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.